Bristol-Myers Squibb Company PFD CONV 2
BMYMP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $48,300 | $45,006 | $46,159 | $46,385 |
| % Growth | 7.3% | -2.5% | -0.5% | – |
| Cost of Goods Sold | $20,868 | $19,649 | $19,669 | $19,624 |
| Gross Profit | $27,432 | $25,357 | $26,490 | $26,761 |
| % Margin | 56.8% | 56.3% | 57.4% | 57.7% |
| R&D Expenses | $9,782 | $9,207 | $9,411 | $9,533 |
| G&A Expenses | $6,365 | $0 | $0 | $0 |
| SG&A Expenses | $7,865 | $7,678 | $7,808 | $7,688 |
| Sales & Mktg Exp. | $1,500 | $0 | $0 | $0 |
| Other Operating Expenses | $127 | $0 | $0 | $0 |
| Operating Expenses | $17,774 | $16,885 | $17,219 | $17,221 |
| Operating Income | $9,658 | $8,472 | $9,271 | $9,540 |
| % Margin | 20% | 18.8% | 20.1% | 20.6% |
| Other Income/Exp. Net | -$18,037 | -$32 | -$1,558 | -$1,442 |
| Pre-Tax Income | -$8,379 | $8,440 | $7,713 | $8,098 |
| Tax Expense | $554 | $400 | $1,368 | $1,084 |
| Net Income | -$8,948 | $8,025 | $6,327 | $6,994 |
| % Margin | -18.5% | 17.8% | 13.7% | 15.1% |
| EPS | -4.41 | 3.88 | 2.97 | 3.15 |
| % Growth | -213.7% | 30.6% | -5.7% | – |
| EPS Diluted | -4.41 | 3.86 | 2.95 | 3.12 |
| Weighted Avg Shares Out | 2,027 | 2,069 | 2,130 | 2,221 |
| Weighted Avg Shares Out Dil | 2,027 | 2,078 | 2,146 | 2,245 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,947 | $1,166 | $1,232 | $1,334 |
| Depreciation & Amortization | $9,600 | $9,760 | $10,276 | $10,686 |
| EBITDA | $3,168 | $19,366 | $19,221 | $20,118 |
| % Margin | 6.6% | 43% | 41.6% | 43.4% |